drugset / Trial / NCT02520752
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
Drg-drug Interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors
Timeline
- Start
- 2015-12-10
- Primary completion
- 2017-01-30
- Completion
- 2017-09-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caffeine | Small molecule | — | — |
| Subject | Capmatinib | Small molecule | — | — |
| Subject | Midazolam | Small molecule | — | — |
Indications
No indication recorded.